Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.
Ecteinascidin-743 (ET-743) is a tetrahydroisoquinoline alkaloid isolated from Ecteinascidia turbinata, a tunicate growing in mangrove roots in Caribbean. It has been shown to bind in the minor groove of DNA forming covalent adducts by reaction of the N2 of guanine with the carbinolamine moiety. We investigated ET-743 ability to inhibit the binding of different transcription factors to their consensus sequences by using gel shift assays. We have selected three types of factors: (i) oncogene products such as MYC, c-MYB and Maf; (ii) transcriptional activators regulated during the cell cycle as E2F and SRF; and (iii) general transcription factors such as TATA binding protein (TBP), Sp1 and NF-Y. We observed no inhibition of the binding of Sp1, Maf, MYB and MYC. Inhibition of DNA binding was observed for TBP, E2F, SRF at ET-743 concentrations ranging from 50 to 300 microM. The inhibition of binding of NF-Y occurs at even lower concentrations (i.e. 10-30 microM) when the recombinant subunits of NF-Y are preincubated with the drug, indicating that the inhibition of NF-Y binding does not require previous ET-743 DNA binding. Since NF-Y is a trimer containing two subunits with high resemblance to histones H2B and H2A, we have investigated the effect of ET-743 on nucleosome reconstitution. ET-743 caused a decrease of the nucleosomal band at 100 nM, with the complete disappearance of the band at 3-10 microM. These data suggest that the mode of action of this novel anticancer drug is related to its ability to modify the interaction between some DNA binding proteins and DNA.
Bonfanti
M
M
Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
La Valle
E
E
Fernandez Sousa Faro
J M
JM
Faircloth
G
G
Caretti
G
G
Mantovani
R
R
D'Incalci
M
M
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D001483:Base Sequence; D022762:CCAAT-Enhancer-Binding Proteins; D016384:Consensus Sequence; D004247:DNA / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004149:Dioxoles / Q000494:pharmacology*; D004586:Electrophoresis; D007546:Isoquinolines / Q000494:pharmacology*; D007939:Leukemia L1210 / Q000378:metabolism; D051379:Mice; D009841:Oligonucleotides / Q000037:antagonists & inhibitors / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D016329:Sp1 Transcription Factor / Q000037:antagonists & inhibitors / Q000378:metabolism; D035181:TATA-Box Binding Protein; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin; D014157:Transcription Factors / Q000037:antagonists & inhibitors / Q000378:metabolism*
D018906:Antineoplastic Agents, Alkylating; D022762:CCAAT-Enhancer-Binding Proteins; D004268:DNA-Binding Proteins; D004149:Dioxoles; D007546:Isoquinolines; D009841:Oligonucleotides; D011518:Proto-Oncogene Proteins; D016329:Sp1 Transcription Factor; D035181:TATA-Box Binding Protein; D044005:Tetrahydroisoquinolines; D014157:Transcription Factors; D004247:DNA; D000077606:Trabectedin